The Italian GIMEMA working group enrolled new-diagnosed CML patients to explore the effects of imatinib (n = 76) and imatinib plus pegylated IFN-a (n = 419). This evidence concerns the gene IFNA2 and chronic myelogenous leukemia, BCR-ABL1 positive.